Interakcje pomiedzy suplementami diety a lekami. Czesc I. Wplyw skladnikow odzywczych w suplementach diety na dzialanie lekow

• Autorzy: Jarosz M , Wolnicka K.
• Języki publikacji: PL

Słowa kluczowe

PL

interakcje; leki; suplementy diety; skladniki odzywcze; zywienie czlowieka

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2005
• Tom: 32
• Numer: 2
• Opis fizyczny: s.57-65,tab.,bibliogr.

Twórcy

autor

Jarosz M

• Instytut Zywnosci i Zywienie, Warszawa

autor

Wolnicka K.

Bibliografia

• 1. Satre-Abouta J., Kristal H.D., Patterson E.E., et al.: Dietary supplement use and medical conditions. The Vital Study. Am. J. Prev. Med., 2003, 24, 1, 43-51.
• 2. Kost J., Chabros E., Wajszczyk B., i wsp.: Zyw. Czlow. Metab., 2004, 31, Supl. 1, cz II, 86, 87.
• 3. Wold R.S., Lopez S.T., Yau C.L., et al.: J. Am. Diet. Assoc., 2005, 105, 54-63.
• 4. Neuvonen P.J.: Interactions with the absorption of tetracyclines. Drugs., 1976, 11, 1, 45-54
• 5. Fraga Fuentes M.D., Garcia Diaz B., de Juana Velasco P., Bermejo Vicedo N.T.: Influence of foods on the absorbtion of antimicrobial agents. Nutr. Hosp., 1997, 12, 277-288.
• 6. Jung H., Peregrina A.A., Rodriguez J.M., et.al.: The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm. Drug. Dispos., 1997, 18, 5, 459-463.
• 7. Jarosz M., Dzieniszewski J.: Interakcje pomiędzy lekami a żywnością. Warszawa, Borgis, 2004.
• 8. Kara M., Hasinoff B.B., McKay D.W., Campbell N.R.: Clinical and chemical interactions between iron preparations and ciprofloxacin. Br. J. Clin. Pharmacol., 1991 Mar, 31, 3, 257-261.
• 9. Li R.C., Lo K.N., Lam J.S., Lau PY.: Effects of order of magnesium exposure on the postantibiotic effect and bactericidal activity of ciprofloxacin. J. Chemother., 1999 Aug., 11, 4, 243-247.
• 10. McCabeSellers, Handbook of Food- Drug Interactions, CRC, 2003, ISBN 0-8493-1531-X.
• 11. Kirch W., Schäfer-Korting M., Axthelm T., et al.: Interaction of atenolol with furosemide and calcium and aluminum salts. Clin. Pharm. Ther., 1981, 30, 4, 429- 435.
• 12. Weiss A.T., Lewis B.S., Halon D.A., Hasin Y., Gotsman M.S.: The use of calcium with verapamil in the management of supraventricular tachyarrhythmias. Int. J. Cardiol., 1983 Oct, 4, 3, 275-284.
• 13. Bar-Or D., Gasiel Y. :Calcium and calciferol antagonise effect of verapamil in atrial fibrillation. Br. Med. J. (Clin. Res. Ed)., 1981 May 16, 282, 6276, 1585-1586.
• 14. Kuhn M., Schriger D.L.: Low-dose calcium pretreatment to prevent verapamil-induced hypotension. Am. Heart J., 1992 Jul, 124, 1, 231-232.
• 15. Fox J., Della-Santina C.P: Oral verapamil and calcium and vitamin D metabolism in rats: effect of dietary calcium. Am. J. Physiol., 1989 Nov, 257, 5 Pt 1, E632-638.
• 16. Kupfer S., Kosovsky J.D.: Effects of cardiac glycosides on renal tubular transport of calcium, magnesium, inorganic phosphate, and glucose in the dog. J. Clin. Invest., 1965 Jul, 44, 1132-1143.
• 17. Sonnenblick M.,Abraham A.S., Meshulam Z., Eylath U.: Correlation between manifestations of di- goxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. B. Med. J. Clin Res Ed., 1983 Apr., 2, 286, 6371, 1089-1091.
• 18. Leppla D., Browne R., Hill K., Pak C.: Effect of amiloride with or without hydrochlorothiazide on urinary calcium and saturation of calcium salts. J. Clin. Endocrinol. Metab., 1983 Nov, 57, 5, 920-924.
• 19. Campbell N.R., Hasinoff B.B.: Iron supplements: A common cause of drug interactions. Br. J. Clin. Pharmacol., 31, 251-255, 1991.
• 20. Campbell N.R., Hasinoff B.B., Stalts H., et al.: Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann. Intern. Med., 1992 Dec., 15, 117, 12, 1010-1013.
• 21. Shakir K.M., Chute J.P., Aprill B.S., Lazarus A.A.: Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. South. Med. J., 1997 Jun., 90, 6, 637-639.
• 22. Leedman PJ., Stein A.R., Chin WW., Rogers I.T., et al.: Thyroid hormone modulates the interaction between iron regulatory proteins and the ferritin mRNA iron-responsive element. J. Biol. Chem., 1996 May 17, 271, 20, 12017-12023.
• 23. Beard J.L., Borel M.J., Derr J.: Impaired thermoregulation and thyroid function in iron-deficiency anemia. Am. J. Clin. Nutr., 1990 Nov, 52, 5, 813-819.
• 24. Beard J., Borel M., Peterson F.J.: Changes in iron status during weight loss with very-low-energy diets. Am. J. Clin. Nutr., 1997 Jul., 66, 1, 104-110.
• 25. Campbell N.R., Rankine D., Goodrige A.E., Hasinoff BB, Kara M. : Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Br. J. Clin. Pharmacol., 1990 Oct, 30, 4, 599-605. 26. Harkness J.A., Blake D.R.: Penicillamine nephropathy and iron. Lancet., 1982 Dec 18, 2, 8312, 1368-1369.
• 27. Holt G.A. :Food & Drug Interactions. Chicago: Precept Press, 1998, 284.
• 28. Kinlay S., Buckley N.A.: Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity. J. Toxicol. Clin. Toxicol., 1995, 33, 1, 55-59.
• 29. al-Ghamdi S.M., Cameron E.C., Sutton R.A.: Magnesium deficiency: pathophysiologic and clinical overview. Am. J. Kidney. Dis., 1994 Nov., 24, 5, 737-752.
• 30. Toffaletti J.: Clinical chemistry. Anal. Chem., 1991 Jun., 15, 3, 12, 192R-194R.
• 31. Young I.S.,Goh E.M., McKillop U.H., et al.: Magnesium status and digoxin toxicity. Br. J. Clin. Pharmacol., 1991 Dec, 32, 6, 717-721.
• 32. Lewis R.,Durnin C., Mc Lay J., et al.: Magnesium deficiency may be an important determinant of ventricular ectopy in digitalised patients with chronic atrial fibrillation. Br. J. Clin. Pharmacol., 1991 Feb, 31, 2, 200-203.
• 33. Harris J.E.: Interaction of dietary factors with oral anticoagulants: review and applications. J. Am. Diet. Assoc., 1995 May, 95, 5, 580-584.
• 34. Bell R.G., Ren P.: Inhibition by warfarin enantiomers of prothrombin synthesis, protein carboxylation, and the regeneration of vitamin K from vitamin K epoxide. Biochem Pharmacol., 1981 Jul., 15, 30, 14, 1953-1958.
• 35. Ohya Y., Ueno M., Takata Y., et al.: Crossover comparison of the effects of enalapril and Captopril on potassium homeostasis in patients with mild hypertension. Int. J Clin. Pharmacol. Ther., 1994 Dec, 32, 12, 655-659.
• 36. Schwaninger M., Ringleb P., Winter R., et al.: Elevated plasma concentrations of homocysteine in antiepilep- tic drug treatment. Epilepsia., 1999 Mar., 40, 3, 345-350.
• 37. Lewis D.P., Van Dyke D.C., Willhite L.A., et al.: Phenytoin-folic acid interaction. Ann. Pharmacother., 1995 Jul-Aug., 29, 7-8, 726-735.
• 38. Seligman H.: Phenytoin-folic acid interaction: a lesson to be learned. Clin. Neuropharmacol., 1999 Sep-Oct, 22, 5, 268-272.
• 39. Trovato A., Nuhlicek D.N., Midtling J.E.: Drug-nutrient interactions. Am. Fam. Physician., 1991 Nov., 44, 5, 1651-1658.
• 40. Olin B.R. ed.: Drug Facts and Comparisons. St. Louis: Facts & Comparison, 1991.
• 41. Garnett W.R.: New opportunities for the treatment of epilepsy. Am. J. Health. Syst. Pharm., 1995 Jan., 1, 52, 1, 88-91.
• 42. Berge K.G., Canner PL.: Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eu.r J. Clin. Pharmacol., 1991, 40 Suppl 1, S49-51.
• 43. Canner P.L., Berge K.G., Wenger N.K., et al: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol., 1986 Dec., 8, 6, 1245-1255.
• 44. Malloy M.J., Kane J.P, Kunitake S.P, et al.: Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann. Intern. Med., 1987 Nov., 107, 5, 616-623.
• 45. Brown B.G., Bardsley J., Poulin D., et al.: Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am. J. Cardiol., 1997 Jul., 15, 80, 2), 111-115.
• 46. Grundy S.M , Mok H.Y., Zech L., Berman M..: Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid. Res., 1981 Jan., 22, 1, 24-36.
• 47. Zucchero F.J., Hogan M.J. Sommer C.D.: Evaluation of Drug Interactions. EDI First Data Bank, INC., St. Luis, MO, 2002.
• 48. Shenfield G.M.: Oral contraceptives. Are drug interactions of clinical significance? Drug Saf., 1993 Jul., 9, 1, 21-37. Review.
• 49. Back D.J., Orme M.L.: Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet., 1990 Jun., 18, 6, 472-484.
• 50. Kuhnz W., Louton T., Humpel M., et al.: Influence of high doses of vitamin C on the bioavailability and the serum protein binding of levonorgestrel in women using a combination oral contraceptive. Contraception., 1995 Feb., 51, 2, 111-116.
• 51. Zamah N.M., Humpel M., Kuhnz W., et al.: Absence of an effect of high vitamin C dosage on the systemic availability of ethinyl estradiol in women using a combination oral contraceptive. Contraception., 1993 Oct., 48, 4, 377-391.
• 52. Matsui M.S., Rozovski S.J.: Drug-nutrient interaction. Clin. Ther., 1982, 4, 6, 423- 440.
• 53. Briggs M.H.: Megadose vitamin C and metabolic effects of the pill. Br. Med. J. (Clin. Res. Ed)., 1981 Dec., 5, 283, 6305, 1547.
• 54. Barr L.C., et al.: Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol. Psychiatry., 1997 May 1, 41, 9, 949-54
• 55. Goff D.C.: Two cases of hypomania following the addition of L-tryptophan to a monoamine oxidase inhibitor. Am. J. Psychiatry., 1985 Dec., 142, 12, 1487-8.
• 56. Pope H.G., Jonas J.M., Hudson J.I., Kafka M.P.: Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am. J. Psychiatry., 1985 Apr., 142, 4, 491-2.